Welcome to our dedicated page for Takeda Pharm SEC filings (Ticker: TAK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Takeda Pharmaceutical Company Limited SEC filings document its reporting as a foreign private issuer and ADR-listed pharmaceutical company that furnishes Form 6-K current reports and files annual reports on Form 20-F. The filings include English-language earnings reports, financial appendices, press releases and governance notices.
Takeda’s regulatory disclosures cover IFRS consolidated results, outlook commentary, ADR and foreign-issuer reporting status, board and representative-director matters, corporate transformation initiatives, and clinical or regulatory updates for programs such as zasocitinib, rusfertide and oveporexton. The filings also document pipeline-related financial-impact statements, shareholder meeting materials and formal exhibits furnished to the SEC.
Takeda Pharmaceutical presents its 2026 Annual Integrated Report, highlighting FY2025 performance, pipeline progress and sustainability milestones. Core Revenue was 4,505.7 billion yen (about $28.3 billion), down modestly as the VYVANSE loss of exclusivity weighed on sales, while Growth and Launch Products generated 2,313.3 billion yen and over half of total revenue.
Core Operating Profit was 1,172.5 billion yen (about $7.4 billion), supported by an efficiency program delivering roughly 300 billion yen in annualized cost savings. Reported Operating Profit fell 98.2% due to a large provision for AMITIZA antitrust litigation, driving reported EPS to -97 yen, though Core EPS rose to 517 yen.
Management guides FY2026 to low-single-digit Core Revenue decline and a 5–8% Core Operating Profit decline at constant exchange rates as Takeda invests heavily in launches for oveporexton, rusfertide and, later, zasocitinib. The company targets Core Operating Profit margins in the low-to-mid 30s%, a net debt/EBITDA ratio of 2x over time and maintains its progressive dividend, raising it to 200 yen for FY2025 and planning 204 yen for FY2026.
Beyond finances, Takeda emphasizes R&D strength, including positive Phase 3 data for key assets and a late-stage oncology partnership with Innovent. It reports a 58% reduction in Scope 1 and 2 greenhouse gas emissions from a FY2016 baseline, a 10% Scope 3 reduction from FY2022, 2,104 new patients in affordability-based assistance programs and 99.6% on-time, in-full product deliveries, underscoring its focus on patients, people, planet and governance.
Takeda Pharmaceutical Company Limited announced that Julie Kim has been formally appointed Representative Director, President and Chief Executive Officer, completing an 18‑month CEO transition. Shareholders elected her as an internal director at the 150th Annual General Meeting, after which the Board appointed her as CEO.
Former President & CEO Christophe Weber retired from the company and the Board upon conclusion of the meeting. The company highlighted that it has three major product launches planned in the next 12 months and a pipeline of five additional late‑stage innovative assets. The Board now has 11 members, including eight external directors, and key committees are composed solely of external directors.
Takeda Pharmaceutical Company Limited reported the results of its 150th Annual General Meeting of Shareholders. Shareholders received reports on the business report and the consolidated and unconsolidated financial statements for the fiscal year from April 1, 2025 to March 31, 2026, along with the audit results.
They approved an appropriation of surplus that includes a year-end dividend of 100 JPY per share. Shareholders also elected eight directors who are not Audit and Supervisory Committee members, three directors who are Audit and Supervisory Committee members, and one substitute director for that committee.
The meeting further approved payment of bonuses within 260 million JPY in total to two directors who are not Audit and Supervisory Committee members, excluding directors residing outside Japan and external directors. Several directors, including all Audit and Supervisory Committee members, were designated as external directors under the Companies Act.
Takeda Pharmaceutical Company Limited files its annual report for the year ended March 31, 2026, outlining its global specialty pharma business, key risks and capital structure. The company operates in about 80 countries, with 90.4% of revenue generated outside Japan and 48.0% from the U.S. Emerging markets contributed JPY 761.5 billion, or 16.9% of revenue.
Takeda highlights a heavy debt load of JPY 4,881.8 billion, largely from the Shire acquisition, and significant restructuring expenses of JPY 128.1 billion and JPY 70.8 billion in fiscal 2025 and 2026. It records a JPY 31.9 billion impairment on ALUNBRIG and expects further restructuring costs in fiscal 2027–2029.
The report details major risks, including R&D setbacks (such as soticlestat and ALOFISEL), upcoming patent and exclusivity expiries for products like VYVANSE, TRINTELLIX and ENTYVIO, global pricing and reimbursement pressure (including U.S. IRA negotiations for ENTYVIO starting January 2028), supply-chain and manufacturing vulnerabilities, growing cybersecurity threats, and ambitious climate and sustainability targets validated by SBTi.
Takeda Pharmaceutical Company Limited plans to issue 16,989,076 ordinary shares on July 8, 2026 for its Long Term Incentive Plan for employees outside Japan. This includes 10,892,917 new shares and 6,096,159 treasury shares at 5,050 yen per share, totaling 85,794,833,800 yen.
The shares will be allotted to 10,557 employees through restricted stock unit and performance stock unit awards, settled mainly in American depositary shares or cash. The transaction will proceed once the shelf registration is effective and shelf registration supplements are filed.
Takeda Pharmaceutical Company Limited is revising its FY2025 consolidated financial statements to reflect provisions for legal proceedings following a recent AMITIZA antitrust jury verdict in the United States. The company has filed a revised Earnings Report with the Tokyo Stock Exchange and updated related FY2025 financial materials.
Takeda emphasizes that these provisions do not change its Core financial results for FY2025, its FY2026 financial forecast, or Management Guidance. The company also highlights that its fundamental business momentum remains intact, supported by three major product launches planned in the next 12 months.
The year-end dividend for FY2025 remains at JPY 100 per share, and the annual dividend forecast for FY2026 stays at JPY 204 per share. The event occurred after the audit report date under the Japanese Companies Act, so the related provisions are not reflected in those statutory FY2025 financial statements.
Takeda Pharmaceutical Company Limited plans to withdraw its existing Japanese Shelf Registration Statement for new shares and file a new shelf in Japan covering issuance of common stock or disposition of treasury shares. The new shelf supports ongoing grants under Takeda’s Long Term Incentive Plan (LTIP) for employees.
The scheduled issue period runs from June 9, 2026 to June 8, 2027, with a maximum aggregate issue amount of up to JPY 240 billion. Takeda states that transactions under this shelf are tied to the LTIP and are not intended to raise funds, but to deliver shares as compensation. Share dilution from vesting of the LTIP and earlier management stock grant systems in the fiscal year ending March 31, 2027 is expected to be around 1.1% in total.
Takeda Pharmaceutical Company Limited is convening its 150th Annual General Meeting of Shareholders on June 24, 2026 in Osaka and via internet livestream. Shareholders will vote on a year-end dividend, director elections, a substitute Audit and Supervisory Committee member, and director bonuses.
For the year ended March 31, 2026, Takeda reported revenue of JPY 4,505.7 billion, down 1.7%, mainly from U.S. generic competition to ADHD drug VYVANSE, while its other five key business areas grew. Net profit rose sharply to JPY 192.0 billion, and core operating profit was stable at JPY 1,172.5 billion, lifting core EPS to JPY 517.
The Board proposes a year-end dividend of JPY 100 per share, bringing the annual dividend to JPY 200, 4 yen higher than the prior year, and up to JPY 260 million in bonuses for two internal directors, reflecting lower KPI payouts. Takeda guides fiscal 2026 revenue to JPY 4,640.0 billion (+3.0%) but expects lower reported EPS of JPY 104.26 and core EPS of JPY 472 as it reinvests in launches and absorbs a higher tax rate.
Takeda Pharmaceutical Company Limited provides detailed notes to its consolidated and unconsolidated financial statements prepared under IFRS for the year ended March 31, 2026. Consolidated revenue from contracts with customers was JPY 4,505,720 million, driven mainly by gastroenterology, rare diseases, plasma-derived therapies and neuroscience.
Impairment losses on intangible assets associated with products totaled JPY 129,266 million, including JPY 58,173 million for the gamma delta T-cell therapy platform and associated oncology programs and JPY 31,877 million for ALUNBRIG. Other operating expenses were JPY 156,435 million, including restructuring expenses of JPY 70,818 million and a valuation reserve for pre-launch inventories of JPY 50,984 million.
Equity attributable to owners of the Company per share was JPY 4,920.50 and basic earnings per share were JPY 121.75. During the year, Takeda completed a share repurchase program, acquiring a total of 23,367 thousand shares for JPY 99,956 million, and paid cash dividends of JPY 313,233 million, with an additional JPY 158,494 million dividend proposed. The notes also detail goodwill of JPY 5,809,010 million, provisions for litigation of JPY 13,204 million, and a comprehensive breakdown of revenue by product and region.